Literature DB >> 23033530

Treatment outcome, mortality and their predictors among HIV-associated tuberculosis patients.

P Tabarsi1, E Chitsaz, A Moradi, P Baghaei, P Farnia, M Marjani, M Shamai, M Amiri, S Nikaein, D Mansouri, M Masjedi, F Altice.   

Abstract

The risk of death is significantly higher in HIV-infected patients with tuberculosis (TB). This study aims to evaluate the impact of demographic, clinical and laboratory characteristics on the treatment outcome and mortality of TB/HIV co-infected patients in a tertiary TB centre in Iran. In total, 111 patients were recruited from 2004 to 2007. Mycobacteriological studies and demographic, clinical, and laboratory data from all patients were analysed and predictors of unsuccessful outcomes as well as mortality were determined. The mean age for all 111 TB-HIV patients was 38 ± 9 years (range 22-70) and 107 (96.3%) were men; 104 (93.7%) had a history of drug abuse and 96 (86.4%) had a history of imprisonment. The method of HIV transmission was intravenous drug use in 88 (79.3%). Twenty-three (20.7%) had a history of Category 1 (CAT I) TB treatment and six (5.4%) Category 2 (CAT II) treatment. Combination antiretroviral therapy (cART) was given to 48 (43.2%). No significant associations were found between treatment outcomes or mortality and gender, smoking, drug and alcohol abuse, imprisonment, method of transmission, history of CAT I and CAT II treatments, CD4 counts or adverse effects (P > 0.05). Administration of cART led to significantly better outcomes (P < 0.001). Lower serum albumin levels and low body weight were significantly associated with mortality.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23033530      PMCID: PMC3495268          DOI: 10.1258/ijsa.2009.009093

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  19 in total

Review 1.  Impact of tuberculosis on HIV-1 replication, diversity, and disease progression.

Authors:  Kalonji R Collins; Miguel E Quiñones-Mateu; Zahra Toossi; Eric J Arts
Journal:  AIDS Rev       Date:  2002 Jul-Sep       Impact factor: 2.500

2.  Predictors of survival in HIV-infected tuberculosis patients.

Authors:  R W Shafer; A B Bloch; C Larkin; V Vasudavan; S Seligman; J D Dehovitz; G DiFerdinando; R Stoneburner; G Cauthen
Journal:  AIDS       Date:  1996-03       Impact factor: 4.177

3.  Survival in a cohort of human immunodeficiency virus-infected tuberculosis patients in New York City. Implications for the expansion of the AIDS case definition.

Authors:  R Stoneburner; E Laroche; R Prevots; T Singh; S Blum; P Terry; S Reatrice; J Adler
Journal:  Arch Intern Med       Date:  1992-10

4.  Increased mortality and tuberculosis treatment failure rate among human immunodeficiency virus (HIV) seropositive compared with HIV seronegative patients with pulmonary tuberculosis treated with "standard" chemotherapy in Kinshasa, Zaire.

Authors:  J H Perriëns; R L Colebunders; C Karahunga; J C Willame; J Jeugmans; M Kaboto; Y Mukadi; P Pauwels; R W Ryder; J Prignot
Journal:  Am Rev Respir Dis       Date:  1991-10

5.  Incidence of tuberculosis and survival after its diagnosis in patients infected with HIV-1 and HIV-2.

Authors:  Marianne A B van der Sande; Maarten F Schim van der Loeff; Rachel C Bennett; Mary Dowling; Akum A Aveika; Toyin O Togun; Saihou Sabally; David Jeffries; Richard A Adegbola; Ramu Sarge-Njie; Assan Jaye; Tumani Corrah; Samuel McConkey; Hilton C Whittle
Journal:  AIDS       Date:  2004-09-24       Impact factor: 4.177

6.  Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Côte d'Ivoire.

Authors:  A N Ackah; D Coulibaly; H Digbeu; K Diallo; K M Vetter; I M Coulibaly; A E Greenberg; K M De Cock
Journal:  Lancet       Date:  1995-03-11       Impact factor: 79.321

7.  Tuberculosis in patients with the acquired immunodeficiency syndrome. Clinical features, response to therapy, and survival.

Authors:  R E Chaisson; G F Schecter; C P Theuer; G W Rutherford; D F Echenberg; P C Hopewell
Journal:  Am Rev Respir Dis       Date:  1987-09

8.  Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection.

Authors:  P M Small; G F Schecter; P C Goodman; M A Sande; R E Chaisson; P C Hopewell
Journal:  N Engl J Med       Date:  1991-01-31       Impact factor: 91.245

9.  Accelerated course of human immunodeficiency virus infection after tuberculosis.

Authors:  C Whalen; C R Horsburgh; D Hom; C Lahart; M Simberkoff; J Ellner
Journal:  Am J Respir Crit Care Med       Date:  1995-01       Impact factor: 21.405

10.  Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya. Analysis of early (6-month) mortality.

Authors:  P Nunn; R Brindle; L Carpenter; J Odhiambo; K Wasunna; R Newnham; W Githui; S Gathua; M Omwega; K McAdam
Journal:  Am Rev Respir Dis       Date:  1992-10
View more
  11 in total

1.  Effect of smoking history on outcome of patients diagnosed with TB and HIV.

Authors:  Koen Vanden Driessche; Monita R Patel; Nana Mbonze; Martine Tabala; Marcel Yotebieng; Frieda Behets; Annelies Van Rie
Journal:  Eur Respir J       Date:  2014-11-27       Impact factor: 16.671

2.  Diagnostic and Prognostic Value of Serum Albumin for Tuberculosis in HIV Infected Patients Eligible for Antiretroviral Therapy: Datafrom an HIV Cohort Study in India.

Authors:  Gerardo Alvarez-Uria; Manoranjan Midde; Raghavakalyan Pakam; Praveen Kumar Naik
Journal:  Bioimpacts       Date:  2013-09-01

3.  Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.

Authors:  N B Bhatt; C Barau; A Amin; E Baudin; B Meggi; C Silva; V Furlan; B Grinsztejn; A Barrail-Tran; M Bonnet; A M Taburet
Journal:  Antimicrob Agents Chemother       Date:  2014-03-24       Impact factor: 5.191

4.  Initial Antituberculous Regimen with Better Drug Penetration into Cerebrospinal Fluid Reduces Mortality in HIV Infected Patients with Tuberculous Meningitis: Data from an HIV Observational Cohort Study.

Authors:  Gerardo Alvarez-Uria; Manoranjan Midde; Raghavakalyan Pakam; Praveen Kumar Naik
Journal:  Tuberc Res Treat       Date:  2013-08-20

5.  The Bandim TBscore--reliability, further development, and evaluation of potential uses.

Authors:  Frauke Rudolf
Journal:  Glob Health Action       Date:  2014-05-22       Impact factor: 2.640

Review 6.  Adjuvant Efficacy of Nutrition Support During Pulmonary Tuberculosis Treating Course: Systematic Review and Meta-analysis.

Authors:  Zhuang-Li Si; Ling-Ling Kang; Xu-Bo Shen; Yuan-Zhong Zhou
Journal:  Chin Med J (Engl)       Date:  2015-12-05       Impact factor: 2.628

7.  Estimation of Ten-Year Survival of Patients with Pulmonary Tuberculosis Based on the Competing Risks Model in Iran.

Authors:  Mehdi Kazempour-Dizaji; Anoshirvan Kazemnejad; Payam Tabarsi; Farid Zayeri
Journal:  Tanaffos       Date:  2016

8.  Effect of smoking on tuberculosis treatment outcomes: A systematic review and meta-analysis.

Authors:  Abay Burusie; Fikre Enquesilassie; Adamu Addissie; Berhe Dessalegn; Tafesse Lamaro
Journal:  PLoS One       Date:  2020-09-17       Impact factor: 3.240

Review 9.  Determination the Research Priorities in the Field of HIV/AIDS in Iran: A Systematic Review Article.

Authors:  Amin Doosti-Irani; Kourosh Holakouie-Naieni
Journal:  Iran J Public Health       Date:  2016-09       Impact factor: 1.429

10.  Risk Factors Associated with Survival of Pulmonary Tuberculosis.

Authors:  Mehdi Kazempour Dizaji; Anoshirvan Kazemnejad; Payam Tabarsi; Farid Zayeri
Journal:  Iran J Public Health       Date:  2018-07       Impact factor: 1.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.